Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95363fc2cf0b49e7a4aef32d7cb692a1 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
filingDate |
2022-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_134c09a149e57898abd9e9433ff48014 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a82872f132b35cf7f2f3ea0be1b2afb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_767361f3119c232493bba168818c31ae http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3585e73efc01d76b895ccbec0cbe21e0 |
publicationDate |
2022-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2022273662-A1 |
titleOfInvention |
Use of sildenafil and rock inhibitors for treating stroke or sequelae following stroke |
abstract |
The present invention relates to a use of a pharmaceutical composition for treating stroke or sequelae following stroke, the composition comprising a phosphodiesterase type 5 activity inhibitor and a Rho-associated kinase (ROCK) inhibitor. n The present inventors have performed research, based on clinical knowledge related to stroke treatment, in order to use sildenafil and a ROCK inhibitor in combination to treat stroke or sequelae caused by stroke, and as a result, confirmed for the first time that stroke or sequelae caused by stroke were significantly improved when sildenafil and a ROCK inhibitor were co-administered compared to when sildenafil or the ROCK inhibitor was administered by itself. Therefore, it is expected that a pharmaceutical composition according to the present invention will be able to be effectively used for treating or studying stroke or stroke-related sequelae. |
priorityDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |